Alkermes plc

NasdaqGS ALKS

Alkermes plc EBT Margin for the year ending December 31, 2023: 25.34%

Alkermes plc EBT Margin is 25.34% for the year ending December 31, 2023, a 268.40% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
  • Alkermes plc EBT Margin for the year ending December 31, 2022 was -15.05%, a -349.36% change year over year.
  • Alkermes plc EBT Margin for the year ending December 31, 2021 was -3.35%, a 63.97% change year over year.
  • Alkermes plc EBT Margin for the year ending December 31, 2020 was -9.29%, a 44.78% change year over year.
  • Alkermes plc EBT Margin for the year ending December 31, 2019 was -16.83%, a -45.04% change year over year.
Key data
Date EBT Margin Net Income Margin EBITDA Margin EBIT Margin
Market news
Loading...
NasdaqGS: ALKS

Alkermes plc

CEO Mr. Richard F. Pops
IPO Date July 16, 1991
Location Ireland
Headquarters Connaught House
Employees 2,100
Sector Health Care
Industries
Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Similar companies

ITCI

Intra-Cellular Therapies, Inc.

USD 126.89

-0.24%

EOLS

Evolus, Inc.

USD 9.47

-3.37%

DVAX

Dynavax Technologies Corporation

USD 12.48

0.00%

IRWD

Ironwood Pharmaceuticals, Inc.

USD 3.65

-3.18%

NBIX

Neurocrine Biosciences, Inc.

USD 139.51

-2.46%

PCRX

Pacira BioSciences, Inc.

USD 20.55

-2.74%

PBH

Prestige Consumer Healthcare Inc.

USD 75.78

1.54%

PAHC

Phibro Animal Health Corporation

USD 20.28

0.05%

ANIP

ANI Pharmaceuticals, Inc.

USD 54.16

0.43%

COLL

Collegium Pharmaceutical, Inc.

USD 33.18

-1.80%

AMPH

Amphastar Pharmaceuticals, Inc.

USD 38.48

1.48%

StockViz Staff

January 15, 2025

Any question? Send us an email